FibroGen, Inc (FGEN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good, Dan, thank you for standing by. Welcome to FibroGen first quarter 2025 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today. Joanne Greller, please go ahead. Thank you, operator. Good afternoon, everyone. Thank you for joining today to discuss Fibrogen's first quarter 2025 financial and business results. I'm Joanne Greller from LifeSci Advisors. Joining me on today's call are Thayne Wettig, our Chief Executive Officer, and David DeLucia, our Chief Financial Officer. Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward listening statements about Fibrogen. Such statements may include, but are not limited to, our collaborations with AstraZeneca and Acelis, financial guidance, initiation, enrollment, design, conduct, and results of clinical trials, our regulatory strategies and potential regulatory results, our research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risk and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in FibroGen's filings with...